We encourage you to report any issues you encounter while using the website.

Biography

Prof.  Kumar  Selvarajoo
Key Laboratory of Preclinical Research of Antitumor Drugs, Taizhou Institute of Zhejiang University,  China

Title: From Systems Biology to Systems AI: Decoding Cancer Heterogeneity for Predictive Drug Discovery

Abstract:

Cancer is a complex and dynamic disease characterized by extensive molecular heterogeneity, cellular plasticity, and adaptive responses to therapeutic interventions. Despite remarkable advances in high-throughput omics technologies and artificial intelligence (AI), our ability to translate molecular information into reliable therapeutic predictions remains limited. A fundamental challenge is that conventional data-driven approaches predominantly identify statistical associations and differentially expressed genes, often without revealing the underlying regulatory mechanisms that govern cellular behavior. Addressing this challenge requires a shift from descriptive molecular profiling toward mechanistic and predictive understanding of biological systems.

In this keynote, I will discuss how our research has evolved from mechanistic systems biology to the emerging concept of Systems AI, integrating mathematical modeling, stochastic transcriptional regulation, and multimodal machine learning to understand cancer heterogeneity and identify therapeutic opportunities.

I will first highlight how mechanistic modeling can uncover therapeutic vulnerabilities that may be overlooked by conventional experimental approaches. Using tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance as an example, our systems-level computational analyses identified protein kinase C (PKC) signaling as a potential therapeutic intervention point. Subsequent experimental investigations established the involvement of PKCδ in regulating TRAIL sensitivity, illustrating the value of integrating computational predictions with experimental validation to uncover actionable biological mechanisms.

I will then explore how stochastic gene expression contributes to cellular heterogeneity and potentially influences cancer progression. Our investigations of chronic lymphocytic leukemia revealed widespread switch-like gene-expression patterns, termed toggle genes, characterized by distinct ON and OFF expression states. These observations suggest that transcriptional variability and cellular state transitions contain biologically meaningful information that is frequently obscured by population-averaged measurements. Building on this concept, our recent work developed a generalized stochastic transcriptional regulation framework capable of reconstructing ovarian cancer transcriptomes through process-driven simulations. By examining transcriptional and RNA degradation parameters, this approach provides an alternative perspective on the regulatory processes underlying gene-expression differences and variability between normal and malignant tissues.

Beyond mechanistic modeling, I will discuss how integrating diverse molecular and clinical information through AI can improve the interpretation and prediction of therapeutic responses. Our multimodal machine-learning framework, MOMLIN, combines genomic, transcriptomic, clinical, and tumor microenvironment information to identify interpretable biomarkers associated with drug responses in breast cancer. This illustrates the complementary strengths of mechanistic and data-driven approaches in advancing precision oncology.

Finally, I will introduce the broader vision of Systems AI, in which mechanistic models, stochastic simulations, multimodal learning, and experimental perturbations are integrated into an iterative framework for biological discovery. Rather than relying exclusively on statistical correlations, Systems AI seeks to generate biologically interpretable, experimentally testable predictions of cellular behavior and therapeutic responses. Such integration may ultimately support the development of predictive biological digital twins for investigating disease mechanisms, evaluating treatment strategies, and prioritizing therapeutic targets.

Together, these advances highlight a transition from observing molecular changes to understanding, predicting, and potentially controlling complex biological systems, opening new opportunities for mechanistically informed precision medicine and next-generation drug discovery.

Biography:

Kumar Selvarajoo is Chief Scientist and Professor at the Taizhou Institute of Zhejiang University, China, where he leads research integrating systems biology, computational biology, and artificial intelligence (AI) for understanding complex biological systems and advancing drug discovery. Previously, he served as a Senior Principal Investigator at the Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore, and Associate Professor of Systems Immunology at Keio University, Japan. He has also held adjunct faculty appointments at the National University of Singapore and Nanyang Technological University.

His research focuses on mechanistic modeling, stochastic gene regulation, multi-omics integration, and AI-driven approaches to cancer biology, immunology, and precision medicine. His work bridges mathematical and computational predictions with experimental investigations to uncover biological mechanisms and identify potential therapeutic targets. More recently, he has been developing the concept of Systems AI, which integrates mechanistic systems biology with machine learning to enable interpretable and predictive biological discoveries.

Professor Selvarajoo has authored over 100 scientific publications and the Springer book Immuno Systems Biology. He serves on the editorial boards of several international scientific journals and has contributed extensively to interdisciplinary research at the interface of biology, mathematics, and AI.

Copyright © 2026 The Academic Communications, PTE. LTD . All rights reserved.